Madopark Depot

Benserazide Hydrochloride / Levodopa, the active ingredient in Madopark Depot, is a dopamine precursor with dopa‑decaboxylase inhibitor presented as a tablet for oral use. It is indicated for the management of Parkinson's disease and related Parkinsonian syndromes in adult patients.

GNH USA supplies Madopark Depot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Madopark Depot is used in the dopaminergic pathway to treat Parkinsonian disorders.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor deficits associated with secondary Parkinsonism. - Levodopa‑responsive Parkinsonism: provides symptomatic relief by restoring central dopamine levels.

Madopark Depot may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia or vivid dreams - Dry mouth

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Severe psychiatric disturbances (hallucinations, psychosis) - Cardiac arrhythmias - Neuroleptic malignant syndrome (very rare) - Severe hypotension leading to syncope

When prescribing Madopark Depot, clinicians should consider several safety measures.

- Monitor for dyskinesia: adjust dose if involuntary movements appear. - Assess cardiovascular status: watch for orthostatic hypotension and arrhythmias. - Review concomitant MAO‑B inhibitors: avoid combined use due to hypertensive risk. - Adjust dose in renal impairment: reduced clearance may increase plasma levels. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. - Store at room temperature: keep in the original pack, protect from moisture.

Madopark Depot can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block dopamine receptors (e.g., haloperidol): may reduce therapeutic effect. - High‑protein meals taken concurrently: can diminish levodopa absorption.

Moderate Interactions (Monitor Closely): - Sympathomimetic agents (e.g., epinephrine): may exacerbate hypertension. - Antihypertensive drugs: additive blood‑pressure lowering effect. - Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome signs.